Please login to the form below

Not currently logged in
Email:
Password:

BIA elects six new board members

Biotech trade body adds representatives from MedImmune, J&J and more

BIA J and J Patrick VerheyenUK trade body the BioIndustry Association (BIA) has elected six new members to its board.

They comprise senior figures from different member companies of the organisation, which represents the biotech industry in the UK.

The list of new members includes Patrick Verheyen (pictured right), head of Johnson & Johnson's innovation centre in London; Jane Osbourn of AstraZeneca subsidiary MedImmune; and Kevin Cox, CEO of imaging firm Imanova.

The remaining new appointments are Stephen Taylor of Fujifilm Diosynth Biotechnologies; Donna Hackett, director of life sciences consultancy firm KDH BioManagement; and Tim Watts, chief financial officer of Oxford BioMedica.

They will all serve from January 1, 2014, for term of three years.

The BIA also announced several returning board members, including John Brown of Vectura Group and Ian Tomlinson, senior VP of worldwide business development and biopharma research at GlaxoSmithKline.

“The appointees are recognised leaders of our industry and I look forward to working with them to help the BIA meet the needs of the bioscience sector in Europe's strongest bioscience cluster,” said Edward Hodgkin, BIA chairman.

15th October 2013

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
M3 (EU)

M3 was founded in 2000 with the goal of changing the world of medicine through making full use of the...

Latest intelligence

What challenges still face clinical trial recruitment and retention?
Discover the reasons for the current clinical trial recruitment challenges facing pharma and the life sciences industry, and how the search for solutions to the problem continues...
“Fake News” and Credibility in Medical Publishing
Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...

Infographics